Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Clinical trial NCT06469944 · RECRUITING
Trial details
- NCT number
- NCT06469944
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-20
- Primary completion
- 2029-09-12
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.